Year 2012, Volume 42, Issue 3, Pages 367 - 375 2012-03-01

Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin
Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin

Serap YILDIRIM [1] , Ali KARADENİZ [2] , Akar KARAKOÇ [3] , Abdulkadir YILDIRIM [4] , Yıldıray KALKAN [5] , Nejdet ŞİMŞEK [6]

142 790

To evaluate the protective effects of royal jelly (RJ) on the changes caused by cisplatin in paraoxonase-1 (PON-1) and arylesterase (ARE) activities. Materials and methods: Twenty-four Sprague-Dawley rats were divided into 4 groups of 6: control, royal jelly (300 mg kg-1 day-1, cisplatin (7 mg kg-1 body weight), and royal jelly (300 mg kg-1 day-1 plus a single dose of cisplatin (7 mg kg-1 body weight). After the experimental procedures, blood and liver tissue samples were taken from each animal. The effects of RJ and cisplatin were evaluated by PON-1, ARE (in liver homogenates), and serum alanine aminotransferase measurements. The liver tissue was also histologically examined. Results: Administration of cisplatin reduced the PON-1 and ARE activities in the liver. However, in the rats given a pretreatment with RJ before the injection of cisplatin, the reduction caused by the cisplatin in the PON-1 and ARE activities was prevented at a significant level. These biochemical observations were supported by histological findings and suggested that RJ restored the cisplatin-induced structural alterations in the liver tissue by the way of its antioxidant, radical scavenging, and antiapoptotic effects. Conclusion: RJ may be a potential preventive agent against the hepatic toxicity associated with cisplatin therapy.
To evaluate the protective effects of royal jelly (RJ) on the changes caused by cisplatin in paraoxonase-1 (PON-1) and arylesterase (ARE) activities. Materials and methods: Twenty-four Sprague-Dawley rats were divided into 4 groups of 6: control, royal jelly (300 mg kg-1 day-1, cisplatin (7 mg kg-1 body weight), and royal jelly (300 mg kg-1 day-1 plus a single dose of cisplatin (7 mg kg-1 body weight). After the experimental procedures, blood and liver tissue samples were taken from each animal. The effects of RJ and cisplatin were evaluated by PON-1, ARE (in liver homogenates), and serum alanine aminotransferase measurements. The liver tissue was also histologically examined. Results: Administration of cisplatin reduced the PON-1 and ARE activities in the liver. However, in the rats given a pretreatment with RJ before the injection of cisplatin, the reduction caused by the cisplatin in the PON-1 and ARE activities was prevented at a significant level. These biochemical observations were supported by histological findings and suggested that RJ restored the cisplatin-induced structural alterations in the liver tissue by the way of its antioxidant, radical scavenging, and antiapoptotic effects. Conclusion: RJ may be a potential preventive agent against the hepatic toxicity associated with cisplatin therapy.
  • Guo H, Saiga A, Sato M, Miyazawa I, Shibata M, Takahata Y et al. Royal jelly supplementation improves lipoprotein metabolism in humans. J Nutr Sci Vitaminol (Tokyo) 2007; 53: 345-8.
  • Guo H, Ekusa A, Iwai K, Yonekura M, Takahata Y, Morimatsu F. Royal jelly peptides inhibit lipid peroxidation in vitro and in vivo. J Nutr Sci Vitaminol (Tokyo) 2008; 54: 191-5.
  • Şimşek N, Karadeniz A, Bayraktaroğlu AG. Eff ects of L-carnitine, royal jelly and pomegranate seed on peripheral blood cells in rats. Kafk as Univ Vet Fak Derg 2009; 15: 63-9.
  • Türk G, Ateşşahin A, Sönmez M, Ceribaşi AO, Yüce A. Improvement of cisplatin-induced injuries to sperm quality, the oxidant-antioxidant system, and the histologic structure of the rat testis by ellagic acid. Fertil Steril 2008; 89: 1474-81.
  • Gottfried M, Ramlau R, Krzakowski M, Ziolo G, Olechnowicz H, Koubkova L et al. Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: fi nal results. J Th orac Oncol 2008; 3: 152-7.
  • Liao Y, Lu X, Lu C, Li G, Jin Y, Tang H. Selection of agents for prevention of cisplatin-induced hepatotoxicity. Pharmacol Res 2008; 57: 125-31.
  • Jiang M, Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Th er 2008; 327: 300- 7.
  • Cayir K, Karadeniz A, Yildirim A, Kalkan Y, Karakoc A, Keles M et al. Protective eff ect of L-carnitine against cisplatin- induced liver and kidney oxidant injury in rats. Cent Eur J Med 2009; 4: 184-91.
  • Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specifi cities. J Lipid Res 2005; 46: 1239-47.
  • Rosenblat M, Karry R, Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol effl ux, when present in HDL than in lipoprotein- defi cient serum: relevance to diabetes. Atherosclerosis 2006; 187: 74-81.
  • Selek Ş, Alp R, İlhan Alp S, Taşkin A. Relationship between PON1 phenotype and headache duration in migraine patients. Turk J Med Sci 2011; 41: 177-184.
  • Yıldırım A, Aslan Ş, Ocak T, Yıldırım S, Kara F, Şahin YN. Serum paraoxonase/arylesterase activities and malondialdehyde levels in trauma patients. EAJM 2007; 39: 85-8.
  • Toker A, Kadı M, Yıldırım AK, Aksoy H, Akçay F. Serum lipid profi le paraoxonase and arylesterase activities in psoriasis. Cell Biochem Funct 2009; 27: 176-80.
  • Demircioğlu RI, Usta B, Sert H, Muslu B, Gözdemir M. Taurine is protective against oxidative stress during cold ischemia in the rat kidney. Turk J Med Sci 2011; 41: 843-849.
  • Al-Majed AA. Carnitine defi ciency provokes cisplatin-induced hepatotoxicity in rats. Basic Clin Pharmacol Toxicol 2007; 100: 145-50.
  • Zamami Y, Takatori S, Goda M, Koyama T, Iwatani Y, Jin X et al. Royal jelly ameliorates insulin resistance in fructose- drinking rats. Biol Pharm Bull 2008; 31: 2103-7.
  • Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248- 54.
  • Beltowski J, Jamroz-Wisniewska A, Borkowska E, Wojcicka G. Diff erential eff ect of antioxidant treatment on plasma and tissue paraoxonase activity in hyperleptinemic rats. Pharmacol Res 2005; 51: 523-32.
  • Eckerson HW, Wyte CM, La Du BN. Th e human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
  • Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007; 7: 3-18.
  • Kart A, Cigremis Y, Karaman M, Ozen H. Caff eic acid phenethyl ester (CAPE) ameliorates cisplatin-induced hepatotoxicity in rabbit. Exp Toxicol Pathol 2010; 62: 45-52.
  • Şanlı A, Aydın S, Sarısoy ZA, Paksoy M, Ayduran E, Erdivanli ÖÇ. Th e protective eff ect of dexamethasone and lactate against cisplatin-induced ototoxicity. Turk J Med Sci 2011; 41: 467-74.
  • Gonzalvo MC, Gil F, Hernandez AF, Rodrigo L, Villanueva E, Pla A. Human liver paraoxonase (PON1): subcellular distribution and characterization. J Biochem Mol Toxicol 1998; 12: 61-9.
  • Ferré N, Camps J, Prats E, Vilella E, Paul A, Figuera L et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin Chem 2002; 48: 261-8.
  • Camuzcuoğlu H, Toy H, Vural M, Camuzcuoğlu A, Taşkın A, Çelik H. Serum paraoxonase and arylesterase activities in iron defi ciency anemia during pregnancy. Turk J Med Sci 2011; 41: 185-191.
  • Goswami B, Tayal D, Gupta N, Mallika V. Paraoxonase: a multifaceted biomolecule. Clin Chim Acta 2009; 410: 1-12.
  • Hazar A, Dilmeç F, Göz M, Koçarslan A, Aydın MS, Demirkol AH. Th e paraoxonase 1 (PON1) gene polymorphisms in coronary artery disease in the southeastern Turkish population. Turk J Med Sci 2011; 41: 895-902.
  • Trudel K, Sinnett D, James RW, Delvin E, Amre D, Seidman E, et al. Iron-ascorbic acid-induced oxidant stress and its quenching by paraoxonase 1 in HDL and the liver: comparison between humans and rats. J Cell Biochem 2005; 96: 404-11.
  • Santos NA, Bezerra CS, Martins NM, Curti C, Bianchi ML, Santos AC. Hydroxyl radical scavenger ameliorates cisplatin- induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Cancer Chemother Pharmacol 2008; 61: 145-55.
  • Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol 2009; 61: 223-42.
  • Sadzuka Y, Shoji T, Takino Y. Eff ect of cisplatin on the activities of enzymes which protect against lipid peroxidation. Biochem Pharmacol 1992; 43: 1872-5.
  • Zhang JG, Lindup WE. Role of mitochondria in cisplatin- induced oxidative damage exhibited by rat renal cortical slices. Biochem Pharmacol 1993; 45: 2215-22.
  • Kishimoto S, Miyazawa K, Terakawa Y, Ashikari H, Ohtani A, Fukushima S et al. Cytotoxicity of cis-[((1R,2R)-1,2- cyclohexanediamine-N,N’)bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line. Jpn J Cancer Res 2000; 91: 1326-32.
  • Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin- induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59: 657-63.
  • Yüce A, Ateşşahin A, Ceribaşi AO, Aksakal M. Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol 2007; 101: 345-9.
Primary Language tr
Journal Section Articles
Authors

Author: Serap YILDIRIM

Author: Ali KARADENİZ

Author: Akar KARAKOÇ

Author: Abdulkadir YILDIRIM

Author: Yıldıray KALKAN

Author: Nejdet ŞİMŞEK

Dates

Publication Date: March 1, 2012

Bibtex @ { tbtkmedical147098, journal = {Turkish Journal of Medical Sciences}, issn = {1300-0144}, eissn = {1303-6165}, address = {TUBITAK}, year = {2012}, volume = {42}, pages = {367 - 375}, doi = {}, title = {Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin}, key = {cite}, author = {YILDIRIM, Serap and KARADENİZ, Ali and KARAKOÇ, Akar and YILDIRIM, Abdulkadir and KALKAN, Yıldıray and ŞİMŞEK, Nejdet} }
APA YILDIRIM, S , KARADENİZ, A , KARAKOÇ, A , YILDIRIM, A , KALKAN, Y , ŞİMŞEK, N . (2012). Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin. Turkish Journal of Medical Sciences, 42 (3), 367-375. Retrieved from http://dergipark.org.tr/tbtkmedical/issue/12298/147098
MLA YILDIRIM, S , KARADENİZ, A , KARAKOÇ, A , YILDIRIM, A , KALKAN, Y , ŞİMŞEK, N . "Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin". Turkish Journal of Medical Sciences 42 (2012): 367-375 <http://dergipark.org.tr/tbtkmedical/issue/12298/147098>
Chicago YILDIRIM, S , KARADENİZ, A , KARAKOÇ, A , YILDIRIM, A , KALKAN, Y , ŞİMŞEK, N . "Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin". Turkish Journal of Medical Sciences 42 (2012): 367-375
RIS TY - JOUR T1 - Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin AU - Serap YILDIRIM , Ali KARADENİZ , Akar KARAKOÇ , Abdulkadir YILDIRIM , Yıldıray KALKAN , Nejdet ŞİMŞEK Y1 - 2012 PY - 2012 N1 - DO - T2 - Turkish Journal of Medical Sciences JF - Journal JO - JOR SP - 367 EP - 375 VL - 42 IS - 3 SN - 1300-0144-1303-6165 M3 - UR - Y2 - 2019 ER -
EndNote %0 Turkish Journal of Medical Sciences Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin %A Serap YILDIRIM , Ali KARADENİZ , Akar KARAKOÇ , Abdulkadir YILDIRIM , Yıldıray KALKAN , Nejdet ŞİMŞEK %T Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin %D 2012 %J Turkish Journal of Medical Sciences %P 1300-0144-1303-6165 %V 42 %N 3 %R %U
ISNAD YILDIRIM, Serap , KARADENİZ, Ali , KARAKOÇ, Akar , YILDIRIM, Abdulkadir , KALKAN, Yıldıray , ŞİMŞEK, Nejdet . "Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin". Turkish Journal of Medical Sciences 42 / 3 (March 2012): 367-375.
AMA YILDIRIM S , KARADENİZ A , KARAKOÇ A , YILDIRIM A , KALKAN Y , ŞİMŞEK N . Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin. Turkish Journal of Medical Sciences. 2012; 42(3): 367-375.
Vancouver YILDIRIM S , KARADENİZ A , KARAKOÇ A , YILDIRIM A , KALKAN Y , ŞİMŞEK N . Effects of royal jelly on liver paraoxonase activity in rats treated with cisplatin. Turkish Journal of Medical Sciences. 2012; 42(3): 375-367.